# Efficacy of Lapaquistat Acetate Co-Administered With Current Lipid-Lowering Treatment on Blood Cholesterol Levels in Subjects With Homozygous Familial Hypercholesterolemia

> **NCT00263081** · PHASE3 · TERMINATED · sponsor: **Takeda** · enrollment: 44 (actual)

## Conditions studied

- Hypercholesterolemia

## Interventions

- **DRUG:** Lapaquistat acetate and current lipid-lowering treatment
- **DRUG:** Current lipid-lowering treatment

## Key facts

- **NCT ID:** NCT00263081
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-11
- **Primary completion:** 2007-03
- **Final completion:** 2007-03
- **Target enrollment:** 44 (ACTUAL)
- **Why stopped:** Overall profile of the compound does not offer significant clinical advantage to patients over currently available lipid lowering agents
- **Last updated:** 2012-05-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00263081

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00263081, "Efficacy of Lapaquistat Acetate Co-Administered With Current Lipid-Lowering Treatment on Blood Cholesterol Levels in Subjects With Homozygous Familial Hypercholesterolemia". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00263081. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*